“Skinny Labeling” and Medicare
“Skinny labeling” is a practice by which follow-on drug manufacturers seek approval for some but not all indications for which branded drugs are approved. Medicare saved $1.5 billion between 2015 and 2020 as a result of competition between five biologic drugs and their skinny-label biosimilars. Recent judicial rulings are threatening these savings for Medicare and […]